share_log

Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO

リガンドファーマシューティカルズは、ZELSUVMIの商業化を加速するためにペルトス・セラピューティクスを立ち上げ、スコット・プレシャ氏がCEOに任命されることを発表しました。

Benzinga ·  04/03 09:05

Pharmaceutical executive Scott Plesha named CEO

Lead product ZELSUVMI expected to be commercially available in late 2024

Ligand Pharmaceuticals (NASDAQ:LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.

This press release features multimedia. View the full release here:

Scott Plesha, CEO, Pelthos Therapeutics (Photo: Business Wire)

Pelthos is committed to commercializing innovative, safe, and efficacious therapeutic products to help patients impacted by diseases with limited treatment options. The company's lead product is ZELSUVMI (berdazimer) topical gel, 10.3%, for the treatment of...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする